Explore 3 Stock Ideas & Industry Insights Download Free Report

Vaxxinity Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-16T21:00:00Z
VOLUME
257
Market Cap
0.01M

Momentum Score

…

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.02
High
52 Week Price Range
-
Low
0.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
-0.00M
Revenue Per Share
-
Gross Profit TTM
-1.87M
Debt / Equity
1.13
ROE
-150.65%
Net Debt
10.24M
ROCE
-210.58%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -0.06M -75.22M -137.18M -39.96M -14.16M
Net income -0.06M -75.21M -138.01M -35.38M -14.22M
Selling general administrative 22.39M 28.35M 51.83M 12.22M 3.00M
Selling and marketing expenses 22.36M - - - -
Gross profit -2.23M 0.00M -1.87M 0.51M 0.00M
Reconciled depreciation 2.32M 1.68M 1.10M 0.72M 0.11M
Ebit -56.24M -75.98M -125.08M -32.28M -13.66M
Ebitda -54.00M -73.04M -123.96M -37.33M -13.58M
Depreciation and amortization 2.23M 2.94M 1.11M -5.04M 0.08M
Non operating income net other - 0.95M -12.10M - -
Operating income -58.28M -75.98M -125.08M -32.28M -13.66M
Other operating expenses 58.28M 75.98M 125.14M 32.84M 13.66M
Interest expense 0.70M 0.51M 0.84M 1.18M 0.43M
Tax provision - 0.00M 0.00M 0.00M 0.06M
Interest income 2.29M 1.26M 0.01M - -
Net interest income 1.53M 0.74M -0.83M -1.18M -0.43M
Income tax expense -0.06M -0.01M 0.84M -4.58M 0.06M
Total revenue 0.00M 0.00M 0.07M 0.56M 0.00M
Total operating expenses 56.05M 75.98M 123.20M 32.79M 13.66M
Cost of revenue 2.23M 0.00M 1.94M 0.05M 0.00M
Total other income expense net 1.35M 0.76M -12.10M -7.67M -0.50M
Net income from continuing ops -66.00M -75.22M -137.18M -39.96M -14.22M
Net income applicable to common shares - -75.22M -137.18M -39.96M -14.22M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 44.31M 106.40M 166.67M 50.14M 1.59M
Other current assets 2.42M 0.52M 0.34M 0.83M 0.66M
Total liab 30.90M 44.22M 38.05M 137.52M 50.11M
Total stockholder equity 13.41M 62.18M 128.62M -87.38M -48.51M
Deferred long term liab - - - 2.25M -
Other current liab 13.92M 24.14M 23.93M 8.61M 5.41M
Common stock 0.28M 0.28M 0.28M 0.27M 0.27M
Capital stock 0.28M 0.28M 0.28M 0.27M 0.27M
Retained earnings -361.64M -304.70M -229.48M -92.31M -52.35M
Other liab - - 0.24M 27.11M 2.26M
Other assets 0.00M - 0.37M 2.31M -
Cash 4.93M 33.48M 144.88M 31.14M 0.48M
Total current liabilities 17.61M 30.94M 27.49M 37.22M 19.88M
Net debt 10.24M -18.93M -134.19M 7.16M 13.86M
Short term debt 1.91M 1.50M 0.38M 27.59M 13.19M
Short long term debt 1.91M 1.50M 0.38M 27.59M 13.19M
Short long term debt total 15.17M 14.55M 10.70M 38.30M 14.33M
Other stockholder equity 374.76M 366.80M 357.82M 4.66M 3.57M
Property plant equipment - 12.51M 12.17M 12.16M 0.16M
Total current assets 33.23M 93.89M 154.13M 35.67M 1.44M
Net tangible assets - 62.18M 128.62M -87.38M -48.51M
Short term investments 25.46M 53.35M - - -
Net receivables 0.41M 0.41M 0.39M 0.39M 0.30M
Long term debt 13.26M 9.93M 10.32M 10.70M 1.12M
Inventory - 6.12M 8.51M 3.31M -
Accounts payable 1.78M 5.29M 3.19M 1.02M 1.28M
Accumulated other comprehensive income 0.01M -0.20M - - -
Common stock total equity - 0.28M 0.28M - -
Retained earnings total equity - -304.70M -229.48M - -
Non currrent assets other - - 0.17M 2.31M -
Non current assets total 11.08M 12.51M 12.54M 14.47M 0.16M
Capital lease obligations - - - 0.01M 0.03M
Long term debt total - 9.93M 10.32M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 56.46M -54.39M -1.32M -1.48M -52.53M
Change to liabilities - 4.44M 13.13M -0.27M -0.45M
Total cashflows from investing activities 28.84M -54.39M -1.32M -1.48M -1.48M
Net borrowings -1.59M -0.43M -0.81M 6.59M 11.12M
Total cash from financing activities -1.14M -0.17M 196.17M 66.11M 11.14M
Change to operating activities - 7.72M 10.68M -2.50M 0.60M
Net income -56.93M -75.22M -137.18M -39.96M -14.22M
Change in cash -29.53M -110.49M 113.86M 30.72M -1.13M
Begin period cash flow 34.57M 145.06M 31.20M 0.48M 1.60M
End period cash flow 5.04M 34.57M 145.06M 31.20M 0.48M
Total cash from operating activities -57.24M -55.93M -80.99M -33.91M -12.27M
Issuance of capital stock - 0.00M 193.87M 20.42M 0.00M
Depreciation 2.23M 1.68M 1.10M 0.72M 0.11M
Other cashflows from investing activities - -52.53M - - -
Change to inventory - - 8.43M -0.24M -
Change to account receivables -0.00M 0.00M 0.03M -0.03M -0.03M
Sale purchase of stock - 0.26M 59.85M -0.04M 0.00M
Other cashflows from financing activities 0.00M 0.26M 127.86M 71.85M 11.14M
Change to netincome - 8.71M 3.16M 8.01M 1.69M
Capital expenditures 0.80M 1.87M 1.32M 1.48M 1.48M
Change receivables - -0.02M - - -
Cash flows other operating - 4.42M 38.53M - -
Cash and cash equivalents changes - -110.49M -16.20M - -
Change in working capital -8.54M 9.82M 12.88M -2.79M 0.16M
Stock based compensation 0.01M 8.71M 30.41M 1.01M 1.23M
Other non cash items 6.00M -0.93M 3.21M 6.45M 0.46M
Free cash flow -58.04M -57.79M -82.31M -35.39M -12.27M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VAXX
Vaxxinity Inc
-
-%
0.00 - - 4604.90 0.01 1898.03 -1.98
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Vaxxinity Inc

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

505 Odyssey Way, Merritt Island, FL, United States, 32953

254 244 5739

57

Name Title Year Born
Mr. Louis Garfield Reese IV Co-Founder & Exec. Chairman 1983
Ms. Mei Mei Hu J.D. CEO & Director 1984
Dr. Ulo Palm M.D., Ph.D. Chief Medical Officer 1957
Mr. Jason Pesile CPA, M.B.A. Sr. VP of Fin. & Accounting 1973
Mr. Dwayne Soisson VP of Operations NA
Mr. Benjamin Matone VP of Investor Relations NA
Mr. Rene Paula Molina Gen. Counsel & Sec. 1979
Mr. Jon Harrison Chief Gov. Officer NA
Mr. Mark Joinnides Chief of Staff NA
Ms. Amy B. Fix M.B.A., M.S., R.A.C. Chief Regulatory Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…